Skip to main content

Table 2 Comparison between patients with rheumatoid arthritis (RA) with abnormal TyG

From: Fasting triglycerides and glucose index: a useful screening test for assessing insulin resistance in patients diagnosed with rheumatoid arthritis and systemic lupus erythematosus

VariablesRA
Abnormal TyG Index
n = 48
RA
Normal TyG index
n = 47
p
Age (years) mean ± SD54.0 ± 6.853.8 ± 7.50.8
Disease duration (years), mean ± SD10.8 ± 8.912.9 ± 9.20.2
Smoking, n (%)6 (12.5)3 (6.7)0.4
Sedentary lifestyle, n (%)33 (68.8)26 (55.3)0.2
Hypertension, n (%)19 (39.6)13 (27.7)0.2
Duration of hypertension (years), mean ± SD4.8 ± 8.51.7 ± 3.90.02
Menopause, n (%)42 (87.5)36 (76.6)0.1
Body mass index (kg/m2), mean ± SD28.4 ± 3.427.5 ± 3.70.2
Waist (cm), mean ± SD94.1 ± 8.189.0 ± 10.20.008
Total-cholesterol (mg/dL), mean ± SD207.2 ± 42.1185.8 ± 29.70.005
 Total-cholesterol (mmol/L), mean ± SD5.3 ± 1.04.8 ± 0.70.005
HDL-cholesterol (mg/dL), mean ± SD47.5 ± 13.957.1 ± 13.50.001
 HDL-cholesterol (mmol/L), mean ± SD1.2 ± 0.31.4 ± 0.30.001
LDL-cholesterol (mg/dL), mean ± SD122.6 ± 36.6107.3 ± 27.30.02
 LDL-cholesterol (mmol/L), mean ± SD3.1 ± 0.92.7 ± 0.70.02
Uric acid(mg/dL), mean ± SD4.6 ± 1.14.1 ± 1.30.07
 Uric acid(mmol/L), mean ± SD2.7 ± 0.62.4 ± 0.70.07
Fat mass% (DXA results), mean ± SD46.9 ± 4.646.8 ± 5.10.8
Treatments
 Corticosteroid, n (%)34 (70.8)40 (85.1)0.1
 Chloroquine, n (%)7 (14.5)7 (14.8)0.09
 Methotrexate, n (%)25 (53.2)30 (63.8)0.2
 Leflunomide, n (%)14 (29.2)13 (27.7)1.0
 Biologics, n (%)4 (8.3)2 (4.3)0.4
  1. Italic values indicate significance of p value (p < 0.05)
  2. An abnormal TyG index (TyG index > 4.68) suggests insulin resistance; HDL-cholesterol high density lipoprotein-cholesterol, LDL-cholesterol low density lipoprotein-cholesterol, DXA dual-energy X-ray absortiometry, TyG values are expressed in mean and standard deviation SD; comparisons between proportions were calculated by Χ2 test or Fisher´s exact test; comparisons between means by unpaired Student-t test; biologics included in the analysis: adalimumab, rituximab, infliximab